TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29135330

Group type: EXPERIMENTAL
Intervention: miLivingStory
Number of subjects: 86

Group type: COMPARATOR
Intervention: miOwnResources
Number of subjects: 86
Study: 26699594

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 25898782

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol (5 mg bolus doses as needed)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Nurse anesthetist-controlled sedation (ACS) with 2-8 mg/kg/h of propofol
Number of subjects: 281

Group type: COMPARATOR
Intervention: Midazolam (control group) with 2-3 mg for induction and additional 1 mg if required
Number of subjects: 281
Study: 23611222

Group type: EXPERIMENTAL
Intervention: HHT + ATRA + AS2O3
Number of subjects: 35

Group type: COMPARATOR
Intervention: Idarubicin (IDA) + ATRA + AS2O3
Number of subjects: 35
Study: 20510971

Group type: EXPERIMENTAL
Intervention: Aquatic resistance training (n=26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention (n=24)
Number of subjects: 50
Study: 18752856

Group type: EXPERIMENTAL
Intervention: Meropack (absorbable hyaluronic acid packing material)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unpacked sinuses
Number of subjects: 60
Study: 17217818

Group type: EXPERIMENTAL
Intervention: 1-day sodium phosphate bowel preparation
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3-day magnesium sulfate bowel preparation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 12959742

Group type: EXPERIMENTAL
Intervention: Endogenous digoxin synthesis
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tryptophan catabolites
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tyrosine catabolites
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cholesterol:phospholipid ratio
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glycoconjugate levels of RBC membrane
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Immune activation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Free radical generation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Altered glycoconjugate metabolism
Number of subjects: 15
Study: 14746855

Group type: EXPERIMENTAL
Intervention: Surgical drains following radical hysterectomy
Number of subjects: 234
Study: 10198901

Group type: EXPERIMENTAL
Intervention: 50 mg/kg/day x 5 days (Group I)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 200 mg/kg/day x 5 days (Group II)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 400 mg/kg/day x 5 days (Group III)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 200 mg/kg/day x 5 days (second treatment for Group I)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 400 mg/kg/day x 5 days (second treatment for Group II)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Adverse reactions (all groups)
Number of subjects: 59
Study: 7774238

Group type: EXPERIMENTAL
Intervention: E5 (2 mg/kg/day by intravenous infusion 24 hrs apart)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 847
Study: 2195062

Group type: EXPERIMENTAL
Intervention: hGH alone (0.1 mg.kg‐1.d‐1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prednisone alone (0.8 mg.kg‐1.d‐1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prednisone plus hGH
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 669246

Group type: EXPERIMENTAL
Intervention: Powder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nothing
Number of subjects: 0
Study: 31042015

Group type: EXPERIMENTAL
Intervention: Early closure (EC) of ileostomy at 30 days after creation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard closure (SC) of ileostomy at 90 days after creation
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Early closure (EC) of ileostomy
Number of subjects: 86
Study: 27986344

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) to the lung with doses of 50 to 60 Gy in 10-Gy increments.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) to the left lung.
Number of subjects: 50
Study: 25824533

Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (EX/RP) therapy
Number of subjects: 40
Study: 23622121

Group type: EXPERIMENTAL
Intervention: Ragweed AIT 1.5 Amb a 1-U
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Ragweed AIT 6 Amb a 1-U
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Ragweed AIT 12 Amb a 1-U
Number of subjects: 784

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 784
Study: 21199963

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 221
Study: 19847184

Group type: EXPERIMENTAL
Intervention: Right-side injection of 60 mg papaverine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Left-side injection of 60 mg papaverine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bilateral injection of 30 mg papaverine into each side
Number of subjects: 60
Study: 17075239

Group type: EXPERIMENTAL
Intervention: Gambling Task (GT) performance in obese subjects (OS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gambling Task (GT) performance in normal-weight subjects (NWS)
Number of subjects: 20
Study: 15011926

Group type: EXPERIMENTAL
Intervention: Personalized letter plus stage-targeted booklets
Number of subjects: 719

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 719
Study: 11727293

Group type: EXPERIMENTAL
Intervention: High involvement scenario
Number of subjects: 256

Group type: COMPARATOR
Intervention: Low involvement scenario
Number of subjects: 256
Study: 9406296

Group type: EXPERIMENTAL
Intervention: Antegrade cold blood cardioplegia
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Retrograde cold blood cardioplegia
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined antegrade-retrograde cold blood cardioplegia
Number of subjects: 44
Study: 8427167

Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U bolus over 5 minutes)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Streptokinase (1.5 million U over 60 minutes)
Number of subjects: 175
Study: 31378980

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (LNS-LNS)
Number of subjects: 1552

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA) and children received LNS (IFA-LNS)
Number of subjects: 1552

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA) and children received micronutrient powder (MNP) (IFA-MNP)
Number of subjects: 1552

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) and children received no supplements (IFA-Control)
Number of subjects: 1552
Study: 29973375

Group type: EXPERIMENTAL
Intervention: GX-H9 (0.1 mg/kg weekly)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GX-H9 (0.3 mg/kg EOW)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GX-H9 (0.2 mg/kg EOW)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Genotropin (6 µg/kg)
Number of subjects: 45
Study: 27512639

Group type: EXPERIMENTAL
Intervention: 0.5 % ropivacaine (group R, n = 53)
Number of subjects: 106

Group type: COMPARATOR
Intervention: 0.9 % normal saline (group C, n = 53)
Number of subjects: 106
Study: 23733348

Group type: EXPERIMENTAL
Intervention: Theory-based invitation letter
Number of subjects: 375

Group type: COMPARATOR
Intervention: Standard invitation letter
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Motivational leaflet
Number of subjects: 375
Study: 23902589

Group type: EXPERIMENTAL
Intervention: Targeted advance notification and standard invitation
Number of subjects: 9200

Group type: EXPERIMENTAL
Intervention: Standard advance notification and targeted invitation
Number of subjects: 9200

Group type: EXPERIMENTAL
Intervention: Targeted advance notification and targeted invitation
Number of subjects: 9200

Group type: COMPARATOR
Intervention: Standard advance notification and standard invitation
Number of subjects: 9200
Study: 21038649

Group type: EXPERIMENTAL
Intervention: Qishen Huoxue Granules (QHG) + Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 52
Study: 18486352

Group type: EXPERIMENTAL
Intervention: Exercise-related activities
Number of subjects: 187

Group type: COMPARATOR
Intervention: No exercise-related activities
Number of subjects: 187
Study: 17058826

Group type: EXPERIMENTAL
Intervention: Ganneng Dripping Pill (GDP)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Lamivudine (Control)
Number of subjects: 84
Study: 12837560

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 200 mg administered rectally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Topiramate (TPM) 100 mg administered orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Topiramate (TPM) 200 mg administered orally
Number of subjects: 12
Study: 10719658

Group type: EXPERIMENTAL
Intervention: Psychoeducational psychotherapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 106
Study: 8651472

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 1% (Tilarin), QID, 1 spray per nostril
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 1% (Tilarin), QID
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 1640161

Group type: EXPERIMENTAL
Intervention: Attribution retraining
Number of subjects: 29

Group type: COMPARATOR
Intervention: Neutral feedback
Number of subjects: 29
Study: 6424997

Group type: EXPERIMENTAL
Intervention: Bupropion, 100 mg by mouth three times a day for 9 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Imipramine, 25 mg by mouth three times a day for 9 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bupropion, 25 mg/kg subcutaneously for 16 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Desipramine, 5 mg/kg subcutaneously for 16 days
Number of subjects: 8
Study: 31516127

Group type: EXPERIMENTAL
Intervention: Medisafe app (intervention group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 51
Study: 29579345

Group type: EXPERIMENTAL
Intervention: Prebiotic formula (PF, n = 60)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Regular formula (RF, n = 60)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Prebiotic formula (PF)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Breastfed (BF)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Regular formula (RF)
Number of subjects: 180
Study: 26643793

Group type: EXPERIMENTAL
Intervention: Supervised training and home‐based rehabilitation program plus educational‐behavioral therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Educational‐behavioral therapy alone
Number of subjects: 46
Study: 25509727

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at qijie area combined with spine balance-regulating massage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medication group (oral nimodipine 30 mg three times a day and vinpocetine injection with glucose or saline)
Number of subjects: 100
Study: 23043451

Group type: EXPERIMENTAL
Intervention: Arginine L-alpha-ketoglutarate, methylsulfonylmethane, hydrolyzed type I collagen and bromelain (Group I)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Not applicable (Group II - no supplement)
Number of subjects: 90
Study: 20372900

Group type: EXPERIMENTAL
Intervention: Low central venous pressure (LCVP) technique, CVP maintained below 5 mmHg or 40% lower than baseline during the preanhepatic phase.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Low central venous pressure (LCVP) technique
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 86
Study: 17509164

Group type: EXPERIMENTAL
Intervention: Doxorubicin/pemetrexed followed by docetaxel (AP-Doc)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Doxorubicin/cyclophosphamide followed by docetaxel (AC-Doc)
Number of subjects: 178
Study: 15650645

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg every 8 hours for 7 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12085384

Group type: EXPERIMENTAL
Intervention: Surveillance with correction of stenosis before thrombosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood flow determination as surveillance method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound dilution for blood flow measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surveillance programs
Number of subjects: 0
Study: 10613424

Group type: EXPERIMENTAL
Intervention: Amino acid mixture solution (L‐arginine hydrochloride 100 mg x kg(‐1) + L‐ornithine hydrochloride 80 mg x kg(‐1) + L‐branched chain amino acids 140 mg x kg(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (P1‐AS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amino acid mixture solution (AS)
Number of subjects: 10
Study: 7598296

Group type: EXPERIMENTAL
Intervention: Naloxone infusions
Number of subjects: 29
Study: 2193123

Group type: EXPERIMENTAL
Intervention: Nipple stimulation (NS)
Number of subjects: 0
Study: 350501

Group type: EXPERIMENTAL
Intervention: 0.1% dithranol in a 17% urea base (Psoradrate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Base alone (17% urea)
Number of subjects: 8
Study: 30698299

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of amygdalin at 0.6 mg/kg bw
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of amygdalin at 3.0 mg/kg bw
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Consumption of crushed bitter apricot seeds at 60 mg/kg bw
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Consumption of crushed bitter apricot seeds at 300 mg/kg bw
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no amygdalin)
Number of subjects: 60
Study: 30233114

Group type: EXPERIMENTAL
Intervention: Integrated yoga therapy module practices, 1 h/day, 5 days a week for 6 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Physical exercises for 1 h/day, 5 days a week for 6 weeks
Number of subjects: 88
Study: 26755201

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (LPP)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Short-term psychodynamic psychotherapy (SPP)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Solution-focused therapy (SFT)
Number of subjects: 326
Study: 25440797

Group type: EXPERIMENTAL
Intervention: CHW-based intervention package (education tools to enhance self-care and adherence, and regular follow-up by the CHW)
Number of subjects: 806

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 806
Study: 21425210

Group type: EXPERIMENTAL
Intervention: Elemental Formula (EF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Polymeric Formula (PF)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both EF and PF
Number of subjects: 34
Study: 21144356

Group type: EXPERIMENTAL
Intervention: Pneumatic video-otoendoscopic examination (VOE)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Still examination group (control)
Number of subjects: 29
Study: 17394891

Group type: EXPERIMENTAL
Intervention: Self etching priming agent (Xeno III)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional acid etch and Prime and Bond
Number of subjects: 60
Study: 17167134

Group type: EXPERIMENTAL
Intervention: Inactivated vaccine
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: Live attenuated vaccine
Number of subjects: 1247
Study: 12868045

Group type: EXPERIMENTAL
Intervention: AAS self-administration for 8 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: AAS self-administration for 12-16 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (200 mg/wk i.m.) for 8 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: AAS administration regimen and length of abuse
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Echocardiographic evaluation
Number of subjects: 48
Study: 10360909

Group type: EXPERIMENTAL
Intervention: Medical evacuation using misoprostol
Number of subjects: 635

Group type: COMPARATOR
Intervention: Surgical evacuation
Number of subjects: 635
Study: 7491378

Group type: EXPERIMENTAL
Intervention: Carbamazepine plus lithium [CBZ‐Li]
Number of subjects: 33

Group type: COMPARATOR
Intervention: Haloperidol plus lithium [HAL‐Li]
Number of subjects: 33
Study: 1772727

Group type: EXPERIMENTAL
Intervention: Subcutaneous suture including a stitch in the fascia
Number of subjects: 35

Group type: COMPARATOR
Intervention: Subcutaneous suture not including a stitch in the fascia
Number of subjects: 35
Study: 6175340

Group type: EXPERIMENTAL
Intervention: Xenon arc laser photocoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Argon laser photocoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral retinal ablation (argon and xenon groups)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panphotocoagulation (argon and xenon groups)
Number of subjects: 0
Study: 29901422

Group type: EXPERIMENTAL
Intervention: Artificial cerebrospinal fluid (ACF) irrigation
Number of subjects: 342

Group type: COMPARATOR
Intervention: Normal saline (NS) irrigation
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Both ACF and NS groups
Number of subjects: 342
Study: 28627976

Group type: EXPERIMENTAL
Intervention: Rocuronium administered based on fat-free mass
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rocuronium administered based on real body weight
Number of subjects: 60
Study: 25862360

Group type: EXPERIMENTAL
Intervention: Self-expanding stents (SES) with distal embolic protection devices (EPD)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Balloon-expandable stents (BES) without EPD
Number of subjects: 127
Study: 24059911

Group type: COMPARATOR
Intervention: Quinine + clindamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative artemisinin-based combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Same first-line artemisinin-based combination therapy
Number of subjects: 0
Study: 20801439

Group type: EXPERIMENTAL
Intervention: GnRH agonist inducing a hypogonadic state during IVF-ET cycles
Number of subjects: 108

Group type: COMPARATOR
Intervention: Controlled ovarian stimulation protocols
Number of subjects: 108
Study: 19694927

Group type: EXPERIMENTAL
Intervention: 100 mg Udenafil
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 200 mg Udenafil
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 17426277

Group type: EXPERIMENTAL
Intervention: 75 microg rHA0 vaccine (15 microg H1, 45 microg H3)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: 135 microg rHA0 vaccine (45 microg each of H1, H3, B)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 460
Study: 15285978

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 10502022

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 8886414

Group type: EXPERIMENTAL
Intervention: 30 mg TAK-044
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 750 mg TAK-044
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1860682

Group type: EXPERIMENTAL
Intervention: Antithrombin III supplementation (3,000 units before hemodialysis)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Antithrombin III supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no antithrombin III supplementation)
Number of subjects: 24
Study: 6849754

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxprenolol (80 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31769635

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 723

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Both positions
Number of subjects: 723
Study: 29600887

Group type: EXPERIMENTAL
Intervention: Dolichoectasia
Number of subjects: 1089

Group type: COMPARATOR
Intervention: No dolichoectasia
Number of subjects: 1089
Study: 26137496

Group type: EXPERIMENTAL
Intervention: Mindful awareness practices (MAP), 8 weekly sessions
Number of subjects: 29

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 29
Study: 22664804

Group type: EXPERIMENTAL
Intervention: Tissue Doppler systolic indices
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Strain (S) and Strain Rate (SR) imaging
Number of subjects: 100
Study: 20857772

Group type: EXPERIMENTAL
Intervention: Therapeutic chair massage and patient teaching in diaphragmatic breathing
Number of subjects: 0
Study: 18578173

Group type: EXPERIMENTAL
Intervention: Ultreo toothbrush used according to manufacturer's instructions for 2 minutes
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ultreo toothbrush (power turned off) used like a manual toothbrush for 2 minutes
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Ultreo toothbrush held approximately 3 mm from tooth surfaces for 2 minutes by a dental hygienist
Number of subjects: 31

Group type: COMPARATOR
Intervention: Swishing with a dentifrice slurry for 1 minute
Number of subjects: 31
Study: 15786890

Group type: EXPERIMENTAL
Intervention: 2RZ (rifampicin plus pyrazinamide)
Number of subjects: 352

Group type: COMPARATOR
Intervention: 6H (isoniazid)
Number of subjects: 352
Study: 12407127

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg twice a day for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav 1000 mg once a day for 7 days
Number of subjects: 12
Study: 10499899

Group type: EXPERIMENTAL
Intervention: Continuous coronary perfusion with warm blood enriched with esmolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 60
Study: 8711052

Group type: EXPERIMENTAL
Intervention: Group Rational-Emotive Behavior Therapy (9 weekly sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Delayed treatment control group (no intervention during control period)
Number of subjects: 44
Study: 1748109

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA) supplement during the race
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA) supplement during the marathon
Number of subjects: 2